Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Venetoclax Drug Increases the Apoptosis of T and B Acute Lymphoblastic Leukemia Cells by Reducing the Expression of BCL-2

Tari, Kaveh ; Nasimian, Ahmad LU ; Kazi, Julhash U. LU orcid and Abroun, Saied (2023) In International Journal of Molecular and Cellular Medicine 12(3). p.229-241
Abstract

Venetoclax, a specific inhibitor of the BCL2 protein, is administered for the treatment of acute lymphoblastic leukemia. However, despite being utilized in conjunction with chemotherapy, the drug exhibits instances of resistance. The exact mechanisms responsible for this resistance remain relatively obscure. Within the context of this investigation, the study aimed to explore the involvement of anti- and pro-apoptotic proteins as one of the potential mechanisms underlying this resistance phenomenon. Blast cells were extracted from patients diagnosed with B&T acute lymphoid leukemia. Subsequently, these cells were subjected to a cultivation process. Following the cultivation, treatment with the Venetoclax drug was administered to... (More)

Venetoclax, a specific inhibitor of the BCL2 protein, is administered for the treatment of acute lymphoblastic leukemia. However, despite being utilized in conjunction with chemotherapy, the drug exhibits instances of resistance. The exact mechanisms responsible for this resistance remain relatively obscure. Within the context of this investigation, the study aimed to explore the involvement of anti- and pro-apoptotic proteins as one of the potential mechanisms underlying this resistance phenomenon. Blast cells were extracted from patients diagnosed with B&T acute lymphoid leukemia. Subsequently, these cells were subjected to a cultivation process. Following the cultivation, treatment with the Venetoclax drug was administered to both groups of B&T cells. Additionally, one group from each cell type was designated as a control. The relative expression levels of genes BCL-2, MCL-1, and BIM were assessed in comparison to the control group. Annexin V–fluorescein isothiocyanate and propidium iodide staining was done to check cell apoptosis. The results showed a significant increase in the expression of BIM gene and a significant decrease in BCL-2 gene compared to the control group, but the change in the expression of MCL-1 gene was not significant. Also, an increase in apoptosis was observed in the treatment groups compared to the control. Although it was shown that changes in the expression of pro- and anti-apoptotic genes can lead to an increase in cell apoptosis and a decrease in the number of blast cells, more studies are needed to investigate the simultaneous effect of Venetoclax drug with other drugs and also in the form of a clinical trial.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
acute lymphoblastic leukemia, apoptosis, BCL-2, Venetoclax
in
International Journal of Molecular and Cellular Medicine
volume
12
issue
3
pages
13 pages
publisher
Babol University of Medical Sciences
external identifiers
  • scopus:85195256507
ISSN
2251-9637
DOI
10.22088/IJMCM.BUMS.12.3.229
language
English
LU publication?
yes
id
1582c386-cd41-4ce9-b027-2acacac69419
date added to LUP
2024-10-14 14:33:03
date last changed
2025-04-04 13:55:26
@article{1582c386-cd41-4ce9-b027-2acacac69419,
  abstract     = {{<p>Venetoclax, a specific inhibitor of the BCL2 protein, is administered for the treatment of acute lymphoblastic leukemia. However, despite being utilized in conjunction with chemotherapy, the drug exhibits instances of resistance. The exact mechanisms responsible for this resistance remain relatively obscure. Within the context of this investigation, the study aimed to explore the involvement of anti- and pro-apoptotic proteins as one of the potential mechanisms underlying this resistance phenomenon. Blast cells were extracted from patients diagnosed with B&amp;T acute lymphoid leukemia. Subsequently, these cells were subjected to a cultivation process. Following the cultivation, treatment with the Venetoclax drug was administered to both groups of B&amp;T cells. Additionally, one group from each cell type was designated as a control. The relative expression levels of genes BCL-2, MCL-1, and BIM were assessed in comparison to the control group. Annexin V–fluorescein isothiocyanate and propidium iodide staining was done to check cell apoptosis. The results showed a significant increase in the expression of BIM gene and a significant decrease in BCL-2 gene compared to the control group, but the change in the expression of MCL-1 gene was not significant. Also, an increase in apoptosis was observed in the treatment groups compared to the control. Although it was shown that changes in the expression of pro- and anti-apoptotic genes can lead to an increase in cell apoptosis and a decrease in the number of blast cells, more studies are needed to investigate the simultaneous effect of Venetoclax drug with other drugs and also in the form of a clinical trial.</p>}},
  author       = {{Tari, Kaveh and Nasimian, Ahmad and Kazi, Julhash U. and Abroun, Saied}},
  issn         = {{2251-9637}},
  keywords     = {{acute lymphoblastic leukemia; apoptosis; BCL-2; Venetoclax}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{229--241}},
  publisher    = {{Babol University of Medical Sciences}},
  series       = {{International Journal of Molecular and Cellular Medicine}},
  title        = {{Venetoclax Drug Increases the Apoptosis of T and B Acute Lymphoblastic Leukemia Cells by Reducing the Expression of BCL-2}},
  url          = {{http://dx.doi.org/10.22088/IJMCM.BUMS.12.3.229}},
  doi          = {{10.22088/IJMCM.BUMS.12.3.229}},
  volume       = {{12}},
  year         = {{2023}},
}